“Next Generation Biologics Market Set To Grow To Over $13bn In 2018” says lead Visiongain analyst

19 July 2018
Pharma

Visiongain has launched a new pharma report Next-Generation Biologics Market 2018-2028:
Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

Biological drugs are distinct from traditional pharmaceutical products, which are derived from chemical precursors or other non-biological sources. Biologics are much larger and more complex molecules than traditional small molecule drugs. While a monoclonal antibody has a size of approximately 150kDa, small molecules drugs are typically around 50 to 100 times smaller than this. Aspirin, for example, has a size of 0.18kDa.

Next-generation biologics are more difficult to define. While the biologics market can be broken into distinct sectors, such as monoclonal antibodies (mAbs), insulins, interferons and growth hormones, there are various development strategies for next-generation biologics in each of these submarkets.

This updated study considers the next generation of biological technologies for applications in human medicine. Developments that fit this definition include half-life extension, engineering to improve target affinity or potency or create multivalent molecules, and reformulations that create new administration options for patients. In some sectors, these strategies have been used for more than a decade. For example, interferon alpha and epoetin alpha molecules were adapted for longer half-lives during the past 10 years. Visiongain predicts the next-generation biologics market will expand throughout the forecast period. Although stricter pricing regulations may prevent the market from achieving revenues close to those of the first-generation therapies, the next-generation biologics market shows high commercial potential. See what its future holds.

We examine the opportunities and challenges that exist within the market, as well as the major commercial trends. We also analyse the market prospects for different segments and provide an overview of the research and development in this sector.

The lead analyst for this report states:

“Next-generation biologic therapies are newer treatments providing novel alternatives to the first-generation biological drugs. With more and more first-generation biologics facing patent expiry, pharmaceutical companies are focusing their resources to innovate and improve technology for production of next-generation biologics. The launch of those medicines will help balance revenue losses from biosimilar drugs.

The next-generation biologics market is set to experience strong revenue growth during our forecasted period, with their demand driven by the rising incidence and prevalence of chronic diseases globally. That market possesses an extensive R&D pipeline, with many candidates progressing to late-stage clinical trials, which will further propel the market in the coming 10 years.”

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever